| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FCGR3A; FCG3; CD16A; FCGR3; IGFR3; IMD20; FCR-10; FCRIII; FCGRIII; FCRIIIA |
| Entrez GeneID | 2214 |
| clone | 2G10A9 |
| WB Predicted band size | 29kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD16 (AA: extra 17-208) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CD16(FcγRIII)抗体的代表性文献，信息简明扼要：
1. **文献名称**：*"Fcγ receptors as regulators of immune responses"*
**作者**：Jeffrey V. Ravetch et al.
**摘要**：该综述系统阐述了CD16(FcγRIII)与其他Fc受体在免疫调节中的作用，重点讨论了其在抗体依赖性细胞介导的细胞毒性(ADCC)中的功能，及其在癌症免疫治疗中的潜在应用。
2. **文献名称**：*"CD16 polymorphism and NK cell mediated cytotoxicity"*
**作者**：Rene A.W. van Lier et al.
**摘要**：研究揭示了CD16(FcγRIIIa)基因多态性(如158V/F突变)对自然杀伤(NK)细胞ADCC活性的影响，为个体化抗体疗法(如利妥昔单抗)的疗效差异提供了分子机制解释。
3. **文献名称**：*"Structural basis for FcγRIIIa recognition of IgG"*
**作者**：P. Rujas et al.
**摘要**：通过X射线晶体学解析CD16与IgG抗体的复合物结构，阐明了其结合表位及亲和力差异，为设计增强ADCC效应的工程化抗体(如奥妥珠单抗)提供了结构生物学依据。
如需扩展，可补充第四篇：
4. **文献名称**：*"Anti-CD16 antibodies for depletion of pro-inflammatory macrophages"*
**作者**：Frederic Geissmann et al.
**摘要**：报道了一种抗CD16单克隆抗体通过靶向清除促炎性巨噬细胞，在炎症性疾病模型(如类风湿性关节炎)中显示出治疗潜力。
以上文献均发表于高影响力期刊(如*Nature Immunology*、*Blood*)，涵盖CD16的基础机制与临床转化研究。
CD16 antibodies target the CD16 antigen, a low-affinity Fc gamma receptor III (FcγRIII) expressed primarily on natural killer (NK) cells, macrophages, neutrophils, and a subset of T cells. CD16 exists as two isoforms: CD16a (FcγRIIIA), a transmembrane protein on NK cells and macrophages, and CD16b (FcγRIIIB), a glycosylphosphatidylinositol (GPI)-anchored form on neutrophils. These receptors bind the Fc region of IgG antibodies, facilitating antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and cytokine release, thereby bridging innate and adaptive immunity.
CD16 antibodies are pivotal in research and therapeutics. In immunotherapy, they enhance NK cell-mediated tumor targeting by engaging CD16a to amplify ADCC, a mechanism exploited by monoclonal antibodies like rituximab and trastuzumab. Conversely, CD16-blocking antibodies may mitigate inflammatory diseases by dampening immune activation. Diagnostic applications include flow cytometry to identify NK cells or monitor receptor density in immune disorders. Recent advances include bispecific antibodies that co-engage CD16 and tumor antigens, redirecting NK cytotoxicity. Challenges include CD16 polymorphism-related variability in antibody binding and effector functions. Overall, CD16 antibodies remain critical tools for modulating immune responses and advancing cancer and autoimmune disease therapies.
×
